



2023 Statistical Data

CancerCare Center

Minot, North Dakota




TRINITY
HEALTH

Trinity Health Statistics - 2023



Each year, the Trinity Health cancer registry reports the annual number of cancer primaries diagnosed and/or treated at Trinity Health. For calendar year 2023, this number is 480 taking the total number of cancer primaries to 15,713 diagnosed and/or treated at Trinity Health since the accession year of 1990.

The following map shows the geographic distribution.



According to *Cancer Facts & Figures 2023* from the American Cancer Society, about 88% of all cancers, in the United States, are diagnosed in persons 50 and older.

In 2023, approximately 86% of all cancers diagnosed at Trinity Health were in persons 50 and older.




2023 Trinity Health Leading Sites of New Cancer Cases

These tables demonstrate that the 10 most common malignancies for 2023 at Trinity Health are consistent with those estimated by the American Cancer society as top sites nationwide for 2023. These 10 sites comprised approximately 79% of all malignancies seen at Trinity Health in 2023.

Male

- Oral Cavity & Pharynx - 4 (2%)
- Lung & Bronchus - 31 (13%)
- Pancreas - 11 (5%)
- Kidney/Renal Pelvis - 8 (3%)
- Urinary Bladder - 3 (1%)
- Colon & Rectum - 33 (14%)
- Prostate - 41 (18%)
- Non-Hodgkin Lymphoma - 12 (5%)
- Melanoma of the Skin - 17 (8%)
- Leukemia - 10 (4%)
- All Other Sites - 63 (27%)



Female

- Thyroid - 11 (4%)
- Lung & Bronchus - 34 (14%)
- Breast - 96 (39%)
- Kidney/Renal Pelvis - 0 (0%)
- Ovary - 1 (1%)
- Uterine Corpus - 11 (4%)
- Colon & Rectum - 26 (11%)
- Non-Hodgkin Lymphoma - 3 (1%)
- Melanoma of the Skin - 16 (6%)
- Leukemia - 10 (4%)
- All Other Sites - 39 (16%)

2024 Estimates – American Cancer Society

Estimated New Cases*

Male		Female	
Oral Cavity & Pharynx 41,510 (4%)	Prostate 299,010 (29%)	Oral Cavity & Pharynx 16,940 (2%)	Urinary Corpus 67,880 (7%)
Colon 54,210 (5%)	Urinary Bladder 63,070 (6%)	Colon 52,380 (5%)	Urinary Bladder 20,120 (2%)
Rectum 27,330 (3%)	Kidney & Renal Pelvis 52,380 (5%)	Rectum 18,890 (2%)	Kidney & Renal Pelvis 29,230 (3%)
Liver & Intrahepatic Bile Duct 28,000 (3%)	Thyroid 12,500 (1%)	Liver & Intrahepatic Bile Duct 13,630 (1%)	Thyroid 31,520 (3%)
Pancreas 34,530 (3%)	Hodgkin Lymphoma 4,630 (<1%)	Pancreas 31,910 (3%)	Hodgkin Lymphoma 3,940 (<1%)
Lung & Bronchus 116,310 (11%)	Non-Hodgkin Lymphoma 44,590 (4%)	Lung & Bronchus 118,270 (12%)	Non-Hodgkin Lymphoma 36,030 (4%)
Melanoma of the Skin 59,170 (6%)	Leukemia 36,450 (4%)	Melanoma of the Skin 41,470 (4%)	Leukemia 26,320 (3%)
Breast 2,790 (<1%)	All Sites 1,029,080 (100%)	Breast 310,720 (32%)	All Sites 972,060 (100%)

*Rounded to nearest 10; cases exclude basal and squamous cell skin cancers and in situ carcinoma except urinary bladder. About 56,500 cases of female breast ductal carcinoma in situ and 99,700 cases of melanoma in situ will be diagnosed in 2024.